Ozempic Prescriptions Rise Among Under-18s

Despite being unapproved for those under 18, the diabetes and weight-loss drug Ozempic is increasingly being prescribed to children and adolescents, raising concerns among health officials.

Data Shows Increase in Prescriptions

Data from the Department of Health, Disability and Ageing reveals that 625 prescribers wrote 2832 prescriptions for Ozempic for individuals under 18 between 2020-21 and 2023-24 through the Pharmaceutical Benefits Scheme (PBS). In 2023-24 alone, 1514 scripts were written.

Clinical Indications Largely Unknown

Due to a lack of comprehensive data, the specific reasons for prescribing Ozempic to this age group remain unclear. Health professionals are concerned about the potential off-label use of the drug in young patients.

Rising Obesity Rates Spark Concern

The rise in prescriptions comes amid growing concerns about childhood obesity. According to the Centers for Disease Control and Prevention (CDC), obesity affects 14.7 million children and adolescents in the United States (CDC).

Ozempic’s Impact on Young People

Ozempic, a brand name for semaglutide, is approved for treating type 2 diabetes in adults. It mimics a hormone that regulates blood sugar and appetite. Its increasing use among younger populations, without clear clinical guidelines, raises questions about long-term effects and appropriate usage.